Endonovo Therapeutics Management
Management criteria checks 3/4
Endonovo Therapeutics' CEO is Alan Collier, appointed in Mar 2012, has a tenure of 12.25 years. total yearly compensation is $850.00K, comprised of 35.3% salary and 64.7% bonuses, including company stock and options. directly owns 11.35% of the company’s shares, worth $67.55K. The average tenure of the management team and the board of directors is 7.3 years and 5 years respectively.
Key information
Alan Collier
Chief executive officer
US$850.0k
Total compensation
| CEO salary percentage | 35.3% |
| CEO tenure | 12.3yrs |
| CEO ownership | 11.3% |
| Management average tenure | 7.3yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$4m |
| Jun 30 2023 | n/a | n/a | -US$4m |
| Mar 31 2023 | n/a | n/a | -US$9m |
| Dec 31 2022 | US$850k | US$300k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$3m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$3m |
| Dec 31 2021 | US$300k | US$300k | -US$3m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$7m |
| Mar 31 2021 | n/a | n/a | -US$7m |
| Dec 31 2020 | US$300k | US$300k | -US$396k |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | -US$11m |
| Dec 31 2019 | US$315k | US$300k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$10m |
| Jun 30 2019 | n/a | n/a | -US$15m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$300k | US$300k | -US$6m |
| Sep 30 2018 | n/a | n/a | -US$6m |
| Jun 30 2018 | n/a | n/a | -US$7m |
| Mar 31 2018 | n/a | n/a | -US$4m |
| Dec 31 2017 | US$789k | US$300k | -US$11m |
Compensation vs Market: Alan's total compensation ($USD850.00K) is about average for companies of similar size in the US market ($USD680.27K).
Compensation vs Earnings: Alan's compensation has increased whilst the company is unprofitable.
CEO
Alan Collier (58 yo)
12.3yrs
Tenure
US$850,000
Compensation
Mr. Alan Brian Collier has been the Chief Executive Officer at Endonovo Therapeutics, Inc. since March 2012 and serves as its Chairman and served as its Secretary since March 2012. He served as Interim Chi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 12.3yrs | US$850.00k | 11.35% $ 67.5k | |
| Vice President of Operations | 12.3yrs | no data | no data | |
| Head of Corporate Development | 2.3yrs | no data | no data | |
| President & Chief Commercial Officer of Medical Division | 1.6yrs | no data | no data |
7.3yrs
Average Tenure
Experienced Management: ENDV's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 12.3yrs | US$850.00k | 11.35% $ 67.5k | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.0yrs
Average Tenure
Experienced Board: ENDV's board of directors are considered experienced (5 years average tenure).